CD8A and cancer: Blockage of the PD-1/PD-L1 or CTLA4 signal with antibodies prevents binding of immunosuppressive molecules to cytotoxic CD8+ T cells, which maintains cytotoxic CD8+ T cell activity against cancer cells [154].